Press Releases – CellCentric

Press and media

Press releases

More regular updates and key information, updates and news can be found on the CellCentric LinkedIn page.

CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma

6 May 2026 Press Release

CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma

31 March 2026 Press Release

CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting

7 December 2025 Press Release

CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

3 November 2025 Press Release

CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma

9 September 2025 Press Release

CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma

3 September 2025 Press Release

CellCentric to Participate in Upcoming Investor Conferences

5 August 2025 Press Release

CellCentric secures $120 million investment to advance inobrodib for treating multiple myeloma

19 May 2025 Press Release

cell-centric-expands-to-US-office-Boston

CellCentric Expands US Presence with New Office in Boston

2 April 2025 Press Release

CellCentric expands executive team with new Chief Strategy Officer

13 January 2025 Press Release

CellCentic Presents Latest Clinical Data at ASH: Promising Efficacy and Safety in Multiple Myeloma

10 December 2024 Press Release

CellCentric to Share Latest Inobrodib Phase II Data; Oral Presentation at ASH 2024

6 November 2024 Press Release

Inobrodib

A first-in-class oral
anti-cancer drug